Cellyan Biotechnology Co. Class AHKPD
13F holders, Q3 2025 (September 30)2holders −4
0new positions
4sold out
$1.47avg. 13F price*
At the end of Q3 2025, 2 institutions reported holding Cellyan Biotechnology Co. Class A (HKPD) in their 13F filings, down 4 from Q2 2025. 0 opened new positions and 4 sold out. The largest holders were Clear Street Group Inc. ($18K) and UBS Group AG ($144).
- Company
- Cellyan Biotechnology Co. Class A
- Filed as
- HONG KONG PHARMA DIGITAL TEC (Q3 2025)
- CUSIP
- G6365B104
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 4 | $51K |
All 13F filers, Q2 2025 → Q3 2025: 61,444 shares sold, net −61,444 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Clear Street Group Inc. | 0.00% | — | 12,019 | $18K |
| UBS Group AG | 0.00% | Reduce -99.5% | 98 | $144 |
"% of holder's portfolio" is HKPD's weight in each manager's 13F, not the share of Cellyan Biotechnology Co. Class A the manager owns.